ReviewEndocrinology and metabolism (Seoul, Korea)2018
Management of Low-Risk Papillary Thyroid Cancer.
Review in Endocrinology and metabolism (Seoul, Korea), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Thermal field management in thyroid ablation for papillary thyroid carcinoma: Advancing precision and patient-centered care.World journal of radiology · 2025Article
- Patient age at diagnosis and biological sex in association with postoperative outcomes of thyroidectomy for low-risk papillary thyroid cancer in the U.S. Military Health System.Gland surgery · 2025Article
- Safety and Effectiveness of Percutaneous Ethanol Injection as a Treatment for Locally Recurrent Papillary Thyroid Carcinoma.International journal of endocrinology and metabolism · 2024Article
- Integrated metabolic and genetic analysis reveals distinct features of primary differentiated thyroid cancer and its metastatic potential in humans.medRxiv : the preprint server for health sciences · 2023Article
- Ethanol Ablation as a Treatment in a Low-Risk Follicular Thyroid Cancer: A Case Report.Cureus · 2022Article
- A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer - A Necessity or an Excess.Frontiers in oncology · 2022Review
- Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Microscopic Extrathyroidal Extension Results in Increased Rate of Tumor Recurrence and Is an Independent Predictor of Patient's Outcome in Middle Eastern Papillary Thyroid Carcinoma.Frontiers in oncology · 2021Article
- Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis.Endocrinology and metabolism (Seoul, Korea) · 2020Article
- Hemithyroidectomy for Thyroid Cancer: A Review.Medicina (Kaunas, Lithuania) · 2020Review
- Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening.Cancers · 2020Article
- Factors Associated with Health Behaviors in Thyroid Cancer Survivors.Journal of cancer prevention · 2020Article
- Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer.Endocrinology and metabolism (Seoul, Korea) · 2020Article
- The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy.International journal of molecular sciences · 2020Review
- US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population.Korean journal of radiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of thyroid cancer has increased, mainly due to the incidental finding of low-risk papillary thyroid cancers (PTC). These malignancies grow slowly, and are unlikely to cause morbidity and mortality. New understanding about the prognosis of tumor features has led to reclassification of many tumors within the low-risk thyroid category, and to the development of a new one "very low-risk tumors." Alternative less aggressive approaches to therapy are now available including active surveillance and minimally invasive interventions. In this narrative review, we have summarized the available evidence for the management of low-risk PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.